Sign in

    John Sheridan

    President, CEO, and Director at Tandem Diabetes Care Inc
    Board
    Since March 2019
    Age
    68 years
    Education
    Holds a B.S. in Chemistry from the University of West Florida and an MBA from Boston University.
    Tenure
    Joined TNDM as Executive Vice President and Chief Operating Officer in April 2013, was promoted to President and CEO in March 2019, and has served on the board of directors since June 2019.

    Also at Tandem Diabetes Care Inc

    EG
    Elizabeth Gasser
    Executive Vice President and Chief Strategy and Product Officer
    JL
    James Leal
    Chief Manufacturing Officer
    JK
    Jean-Claude Kyrillos
    Executive Vice President and Chief Operating Officer

    About

    John Sheridan has built an extensive career in healthcare and technology, having held several key leadership positions prior to joining TNDM. He served in pivotal roles at firms such as Rapiscan Systems, Volcano Corporation, CardioNet (now BioTelemetry), and Digirad Corporation, showcasing his wide-ranging expertise in operations and research & development.

    Throughout his career, his focus on innovation and operational excellence has been evident, as he has successfully steered multiple organizations through periods of transformation. His strategic insights and leadership have contributed to advancements in medical technology and systems, reflecting his commitment to the industries he has served.

    At TNDM, his impactful journey began in April 2013 when he took on the role of Executive Vice President and Chief Operating Officer. His subsequent promotion in March 2019 to President and CEO, along with being appointed to the board of directors in June 2019, underscores his significant contribution in shaping the company’s direction and growth.

    Beyond his role at TNDM, his participation on the board of directors of another company highlights his broader industry influence. His professional narrative not only reveals a strong foundation in operational leadership but also a consistent drive to enhance healthcare technology through innovation and strategic vision.

    $TNDM Performance Under John Sheridan

    Past Roles

    Organization Role Date Range Details
    Tandem Diabetes CareExecutive Vice President and Chief Operating OfficerApril 2013 – March 2019Previous role at TNDM prior to becoming CEO
    Rapiscan Systems, Inc.Chief Operating OfficerMarch 2012 – February 2013Provider of security equipment and systems
    Volcano CorporationExecutive Vice President, Research and Development and OperationsNovember 2004 – March 2010Medical technology company
    CardioNet, Inc. (now BioTelemetry, Inc.)Executive Vice President of OperationsMay 2002 – May 2004Medical technology company
    Digirad CorporationVice President of OperationsMarch 1998 – May 2002Medical imaging company

    External Roles

    Organization Role Date Range Details
    Acutus Medical, Inc.DirectorSince March 2021Arrhythmia management company board role

    Fixed Compensation

    Data from  FY 2023
    Component NameAmountPayment ScheduleAdditional Details
    Base Salary$710,700AnnualFixed annual amount provided for core responsibilities; unchanged from 2022 as no salary increases were applied
    All Other Compensation$11,140AnnualIncludes Group Term Life Insurance Premiums of $4,540 and 401(k) Employer Contributions of $6,600; Other expenses not applicable

    Performance Compensation

    Data from  FY 2023

    Cash Bonus Plan

    ComponentWeight (%)Threshold Payout (% of Target Bonus)Target Payout (% of Target Bonus)Maximum Payout (% of Target Bonus)Actual Achievement/PayoutPayout Amount (USD)Payment Conditions/VestingEvaluation Period
    Financial Performance8050% (at 90% revenue target reached)100% (at revenue target reached)200% (at ≥110% revenue target)0% (threshold not met)$0One-time annual incentive; no vesting2023
    Product Development1050% (upon meeting minimum product launches)100% (target launches)200% (with outperformance)200% (4 new products launched)Contributed 20% to total bonusOne-time annual incentive; no vesting2023
    Customer Satisfaction1050% (upon meeting customer satisfaction metrics)100% (target scores)200% (with outperformance)175%Contributed 17.5% to total bonusOne-time annual incentive; no vesting2023
    Total / Overall100N/AN/AN/A37.5% Total Payout$266,513 (based on base salary of $710,700)One-time annual cash bonus; based on annual performance2023

    Long-Term Incentive (LTI) Equity Compensation Program

    Metric/ComponentDetails/ValueConditions/Vesting DetailsEvaluation Period
    Revenue CAGR ObjectiveWeight: 30%; Payout Factor: 50% at threshold, 100% at target, 200% at maximumBased on 3-year performance (2023–2025); linear interpolation applied between levels2023–2025
    TSR (Total Shareholder Return) ObjectiveWeight: 20%; Payout Factor: 50% at threshold, 100% at target, 200% at maximumComparison against the Russell 3000 Index; performance measured over the same 3-year period; linear interpolation applied2023–2025
    Performance Stock Units (PSUs)65,659 units; Aggregate Value: $1,726,175Vesting contingent on achieving performance metrics; payout occurs in 2026; subject to continued employment2023–2025 (vesting in 2026)
    Restricted Stock Units (RSUs)65,659 units; Aggregate Value: $1,726,175Vesting over a 36-month period: 33% vests on May 25, 2024, and the remaining 67% vests in quarterly installments over the next 24 months; subject to continued employment2023–2025 (vesting starting 2024)
    Grant DetailsGrant Date: May 25, 2023; Grant Date Fair Value: $26.29 per shareNo explicit grant date stock price provided; valuation based on the fair value per share 2023

    These tables provide a comprehensive breakdown of John Sheridan's 2023 performance compensation, covering both the short-term cash bonus plan and the long-term equity compensation components with all available metrics, targets, thresholds, weights, vesting details, and actual payout outcomes where applicable.